Larvol Delta - Tris-Pharma-to-Unveil-Positive-Phase-3-Results-including-a-Strong-Safety-Profile-Showcasing-the-Potential-of-Cebranopadol-an-Investigational-FirstinClass-DualNMR-Agonist-for-the-Treatment-of-Pain-at-the-2025-ASRA-Annual-Meeting

cebranopadol (TRN-228) - Tris Pharma

https://www.businesswire.com/news/home/20250501204234/en/Tris-Pharma-to-Unveil-Positive-Phase-3-Results-including-a-Strong-Safety-Profile-Showcasing-the-Potential-of-Cebranopadol-an-Investigational-First-in-Class-Dual-NMR-Agonist-for-the-Treatment-of-Pain-at-the-2025-ASRA-Annual-Meeting

Apr 30, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next